Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

Csaki Huttner, Angela; Siegrist, Claire-Anne

doi:10.1080/14760584.2018.1546582

Scientific article

English

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

ContributorsCsaki Huttner, Angela; Siegrist, Claire-Anne

Published inExpert Review of Vaccines, vol. 17, no. 12, p. 1105-1110

Publication date2018

Abstract

The live-attenuated recombinant vesicular stomatitis virus vaccine expressing the glycoprotein (GP) of Zaire Ebola virus (rVSV-ZEBOV) has proven immunogenic in humans and effective in field studies. Yet long-term durability of vaccine responses is unknown.

Keywords

Ebola virus disease
Ebola
Vaccine
RVSV-ZEBOV
Immune response
Durability
Persistence
Seropositivity

Affiliation entities

Research groups

Centre de vaccinologie et d'immunologie néonatale (177)

Citation (ISO format)

CSAKI HUTTNER, Angela, SIEGRIST, Claire-Anne. Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know? In: Expert Review of Vaccines, 2018, vol. 17, n° 12, p. 1105–1110. doi: 10.1080/14760584.2018.1546582

Article (Published version)

Identifiers

PID : unige:124456
DOI : 10.1080/14760584.2018.1546582
PMID : 30422031

ISSN of the journal1476-0584

307views

0downloads

Creation09/13/2019 3:39:00 PM

First validation09/13/2019 3:39:00 PM

Update time03/15/2023 6:11:10 PM

Status update03/15/2023 6:11:10 PM

Last indexation10/31/2024 4:33:18 PM

Archive ouverte UNIGE

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

The live-attenuated recombinant vesicular stomatitis virus vaccine expressing the glycoprotein (GP) of Zaire Ebola virus (rVSV-ZEBOV) has proven immunogenic in humans and effective in field studies. Yet long-term durability of vaccine responses is unknown.

Technical informations